<DOC>
	<DOCNO>NCT00166244</DOCNO>
	<brief_summary>Determine value clinically feasible strategy therapeutic drug monitoring compare fixed dose de novo MMF treat renal transplant recipient respect incidence treatment failure .</brief_summary>
	<brief_title>Fixed Dose MMF v Concentration Controlled MMF After Renal Transplantation</brief_title>
	<detailed_description>For treatment mycophenolate mofetil contribution TDM still determine , although circumstantial evidence suggest measurement mycophenolic acid plasma concentration add patient management . A concerted effort test hypothesis TDM improve outcome mycophenolate mofetil therapy prospective randomise trial make want solid base continue measurement mycophenolic acid concentration future . This trial aim demonstrate add value TDM mycophenolic acid , compare fix dose treatment concentration control mycophenolate mofetil treatment kidney transplant recipient .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Renal transplant recipient complete second birthday , Recipients living ( related unrelated ) , cadaveric ( nonheart beat heart beating ) donor , Single organ recipient ( kidney ) , Women childbearing potential negative serum urine pregnancy test sensitivity least 50 mIU/ml within 1 week prior begin MMF treatment . Effective contraception must use begin therapy , therapy 6 week follow discontinuation therapy , even history infertility , unless due hysterectomy , Patients patient 's parent/guardian provide write informed consent , Patients cooperative able complete assessment procedure . Patients receive immunosuppressive therapy ( except steroid treatment ) within precede 28 day , except immunosuppressive medication may initiate 48 hour transplantation . Furthermore , patient receive 1 g [ adult ] 600 mg/m2 [ paediatric patient ] MMF therapy within 6 hour prior transplantation , PRA &gt; 50 % within 6 month prior enrolment , Cold ischaemia time &gt; 48 hour , History malignancy ( except localise nonmelanotic skin cancer ) presence active malignancy time transplant , Active peptic ulcer disease , Active infection , Mandatory intake prohibit drug probable patient require treatment drug transplant , Pregnant lactate female , Women childbearing potential willing use reliable form contraception , Patient allergic intolerant polysorbate 80 ( TWEEN ) , phenylalanine ( aspartame ) , steroid , MMF , MPA , tacrolimus cyclosporin , Patient donor positive test HIV hepatitis B surface antigen , Patients liver cirrhosis clinical evidence portal hypertension indication moderate severe liver disease . ( Note : strongly recommend patient hepatitis C liver biopsy perform prior transplantation ) , Incompatible ABO blood type and/or positive crossmatch , Patient form substance abuse , psychiatric disorder condition , , opinion investigator , may invalidate communication investigator study procedure , Patients whose laboratory result reveal severe anaemia ( define haemoglobin value &lt; 6 mmol/L [ 9.7 g/dL ] adult receive erythropoietin , &lt; 4.1 mmol/L [ 6.6 g/dL ] paediatric patient [ regardless erythropoietin treatment ] ) , leukopenia ( define WBC value &lt; 2500/mm3 ) thrombocytopenia ( defined platelet count &lt; 75,000/mm3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Therapeutic Drug Monitoring</keyword>
	<keyword>Adult kidney transplantation</keyword>
	<keyword>Paediatric kidney transplantation</keyword>
</DOC>